{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:51:28Z","timestamp":1790373088675,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"3","funder":[{"name":"GSK"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,12,3]]},"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis and extrarenal lupus. These biologics, which operate through complementary mechanisms, might result in an enhanced depletion of circulating and tissue-resident autoreactive B lymphocytes when administered together. Thus, belimumab and rituximab combination may be a highly effective treatment of SLE. This study aims to evaluate and compare the efficacy, safety and tolerability of subcutaneous (SC) belimumab and a single cycle of rituximab in patients with SLE with belimumab alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>BLISS-BELIEVE is a three-arm, randomised, double-blind, placebo-controlled, 104-week superiority study. Two hundred adults with SLE will be randomised 1:2:1 to arm A, belimumab SC 200\u2009mg\/week for 52 weeks plus placebo at weeks 4 and 6; arm B, belimumab SC 200\u2009mg\/week for 52 weeks plus rituximab 1000\u2009mg at weeks 4 and 6; arm C, belimumab SC 200\u2009mg\/week plus standard of care for 104 weeks. The 52-week treatment period (arms A and B) is followed by a 52-week observational phase. The primary efficacy endpoint is the proportion of patients with disease control (SLE Disease Activity Index (SLEDAI)\u22122K\u22642, without immunosuppressants and with a prednisone-equivalent dose of \u22645\u2009mg\/day) at week 52. Major secondary efficacy endpoints are the proportion of patients in clinical remission (defined as SLEDAI-2K=0, without immunosuppressants and corticosteroids) at week 64, and the proportion of patients with disease control at week 104. Safety endpoints include the incidence of adverse events (AEs), serious AEs and AEs of special interest.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>Within 6 months of the study\u2019s primary manuscript publication, anonymised individual participant data and study documents can be requested for further research from<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"www.clinicalstudydatarequest.com.\" ext-link-type=\"uri\">www.clinicalstudydatarequest.com.<\/jats:ext-link><\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT03312907\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\">NCT03312907<\/jats:ext-link>; Pre-results.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2018-025687","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T09:40:18Z","timestamp":1553161218000},"page":"e025687","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":98,"title":["Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03312907","registry":"10.18810\/clinical-trials-gov","type":"preResults"},{"clinical-trial-number":"nct02631538","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02260934","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn47873003","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct03312907","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn47873003","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct02260934","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02631538","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03312907","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Y K Onno","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian N","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Groark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"2024051715262254000_9.3.e025687.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.01.001"},{"key":"2024051715262254000_9.3.e025687.2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D\u2019Cruz","year":"2007","journal-title":"The Lancet"},{"key":"2024051715262254000_9.3.e025687.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.106"},{"key":"2024051715262254000_9.3.e025687.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209489"},{"key":"2024051715262254000_9.3.e025687.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139"},{"key":"2024051715262254000_9.3.e025687.6","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"key":"2024051715262254000_9.3.e025687.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/347520","article-title":"Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review","volume":"2013","author":"Oglesby","year":"2013","journal-title":"Int J Rheumatol"},{"key":"2024051715262254000_9.3.e025687.8","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S"},{"key":"2024051715262254000_9.3.e025687.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678"},{"key":"2024051715262254000_9.3.e025687.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.1.6"},{"key":"2024051715262254000_9.3.e025687.11","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315604909"},{"key":"2024051715262254000_9.3.e025687.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"2024051715262254000_9.3.e025687.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2024051715262254000_9.3.e025687.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2024051715262254000_9.3.e025687.15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024051715262254000_9.3.e025687.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2024051715262254000_9.3.e025687.17","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315625119"},{"key":"2024051715262254000_9.3.e025687.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.20592"},{"key":"2024051715262254000_9.3.e025687.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.22211"},{"key":"2024051715262254000_9.3.e025687.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei080"},{"key":"2024051715262254000_9.3.e025687.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430"},{"key":"2024051715262254000_9.3.e025687.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.22046"},{"key":"2024051715262254000_9.3.e025687.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233"},{"key":"2024051715262254000_9.3.e025687.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"2024051715262254000_9.3.e025687.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.24903"},{"key":"2024051715262254000_9.3.e025687.26","doi-asserted-by":"publisher","DOI":"10.1186\/ar2789"},{"key":"2024051715262254000_9.3.e025687.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.22967"},{"key":"2024051715262254000_9.3.e025687.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092791"},{"key":"2024051715262254000_9.3.e025687.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080960"},{"key":"2024051715262254000_9.3.e025687.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079418"},{"key":"2024051715262254000_9.3.e025687.31","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024051715262254000_9.3.e025687.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.21650"},{"key":"2024051715262254000_9.3.e025687.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060772"},{"key":"2024051715262254000_9.3.e025687.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202071"},{"key":"2024051715262254000_9.3.e025687.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008418","article-title":"Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice","volume":"5","author":"Kawabata","year":"2010","journal-title":"PLoS One"},{"key":"2024051715262254000_9.3.e025687.36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2024051715262254000_9.3.e025687.37","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400"},{"key":"2024051715262254000_9.3.e025687.38","doi-asserted-by":"publisher","DOI":"10.1002\/art.27515"},{"key":"2024051715262254000_9.3.e025687.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.2.817"},{"key":"2024051715262254000_9.3.e025687.40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/art.38907","article-title":"Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus","volume":"67","author":"Lin","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024051715262254000_9.3.e025687.41","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2024051715262254000_9.3.e025687.42","first-page":"355","article-title":"Rituximab-refractory lupus nephritis successfully treated with belimumab","volume":"34","author":"Gonzalez-Echavarri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2024051715262254000_9.3.e025687.43","unstructured":"Gualtierotti R , Borghi MO , Gerosa M , et al . Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. Clin Exp Rheumatol 2018;36."},{"key":"2024051715262254000_9.3.e025687.44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu369"},{"key":"2024051715262254000_9.3.e025687.45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jbspin.2016.01.008","article-title":"Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab","volume":"84","author":"Simonetta","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2024051715262254000_9.3.e025687.46","doi-asserted-by":"crossref","unstructured":"Kraaij TKS , de Rooij ENM , Daele PLV , et al . Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE. Arthritis Rheumatol 2017;69.","DOI":"10.1136\/lupus-2018-abstract.172"},{"key":"2024051715262254000_9.3.e025687.47","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2024051715262254000_9.3.e025687.48","unstructured":"BEAT Lupus. https:\/\/beatlupusuk\/."},{"key":"2024051715262254000_9.3.e025687.49","unstructured":"CALIBRATE. About CALIBRATE. http:\/\/calibratestudy.org\/about-calibrate#.Ww7HKbpFzDd"},{"key":"2024051715262254000_9.3.e025687.50","unstructured":"NHS. Interim clinical commissioning policy statement: Rituximab for the treatment of systemic lupus erythematosus in adults. 2013 https:\/\/wwwenglandnhsuk\/wp-content\/uploads\/2013\/10\/a13-ps-apdf."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-025687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T03:50:21Z","timestamp":1716004221000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-025687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,20]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/bmjopen-2018-025687"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-025687","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}